Furthermore, we found that decreased ATF4 and xCT expression in RSL3-treated cells could be prevented by NF-κB pathway inhibition, and NF-κB pathway activation in GPX4-depleted glioblastoma cells reduced ATF4 and xCT expression. The gene discussed is SLC7A11; the disease is glioblastoma.